Targeted therapies in NSCLC, including inhibitors of EGFR, ALK, ROS1 and MET [9, 10, 14], exhibit remarkable precision but face limitations such as the emergence of drug resistance over time, reliance on specific biomarkers for efficacy, potential side effects, limited long-term effectiveness, and challenges related to cost and accessibility [38, 39]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.